Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Katja Weisel*, Meletios Dimopoulos, Philippe Moreau, Munci Yagci, Alessandra Larocca, Abraham S. Kanate, Filiz Vural, Nicola Cascavilla, Supratik Basu, Peter Johnson, Peter Byeff, Marek Hus, Paula Rodríguez-Otero, Ercan Muelduer, Pekka Anttila, Patrick J. Hayden, Maria Theresa Krauth, Paulo Lucio, Dina Ben-Yehuda, Larisa MendeleevaShien Guo, Xin Yu, Lara Grote, Tsvetan Biyukov, Sujith Dhanasiri, Paul Richardson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients. Here, we report health-related quality of life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index were generally stable over time across treatment arms. The proportion of patients who experienced clinically meaningful worsening in global QoL and other domains of interest was similar. These HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.

Original languageAmerican English
Pages (from-to)1850-1859
Number of pages10
JournalLeukemia and Lymphoma
Volume61
Issue number8
DOIs
StatePublished - 2 Jul 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

  • HRQoL
  • Quality of life
  • bortezomib
  • dexamethasone
  • multiple myeloma
  • pomalidomide

Fingerprint

Dive into the research topics of 'Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this